Superworth

Coherus Oncology price to book ratio CHRS

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026
2.6×
10-year median
9.0×
Against its 10-year history
9th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.8× to 80.9×
Peer median
2.7×

Coherus Oncology's price to book ratio is 2.6× as of Oct 23, 2026.

That is below its ten-year median of 9.0×, lower than on 91% of days in the last ten years.

Over that time it ranged from 0.8× in Aug 2025 to 80.9× in Feb 2019.

The median for 10 healthcare stocks of a similar size is 2.7×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.6×1.9×4.9×
20251.8×0.8×1.9×
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
202252.2×7.0×56.7×
20219.4×3.6×10.9×
20204.9×4.7×28.2×
201922.8×22.5×80.9×
201849.0×9.7×67.3×
20179.1×8.3×57.9×
201637.4×12.7×37.6×
201522.0×8.2×36.2×

Against its peers

Companies in Healthcare nearest Coherus Oncology's size, closest first, today.

CompanyPrice to book ratio
CHRSCoherus Oncology2.6×
PDEXPro DEX4.2×
PLXProtalix BioTherapeutics2.9×
NATRNatures Sunshine Products1.3×
ELMDElectromed4.1×
UTMDUtah Medical Products1.9×
KEQUKewaunee Scientific1.3×
ICCCImmucell3.0×
INFUInfuSystem4.7×
LFVNLifevantage2.2×
VMDViemed Healthcare2.6×
Peer median2.7×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Coherus Oncology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.